血清HE4、CA125联合检测对卵巢癌的诊断价值

Diagnostic value of combined detection of serum HE4 and CA125 in ovarian cancer

目的研究肿瘤标记物血清人附睾分泌蛋白4（HE4）与糖类抗原125（CA125）联合检测对卵巢癌的诊断价值。方法选择2013年7月-2015年7月在我院就诊的100例卵巢癌患者为观察组,100例体检健康者为对照组,采用酶联免疫法（ELISA）检测100例不同分期卵巢癌患者及100例健康对照组患者的血清HE4水平,采用化学发光免疫定量分析法（ECLIA）检测CA125水平,检测数据进行统计学分析,探究两标志物单项或联合检测对卵巢癌的诊断价值。结果观察组与对照组相比血清HE4与CA125水平明显升高,差异有统计学意义（P〈0.05）,血清HE4与CA125联合检测的诊断结果显示其敏感性、特异性及准确性分别为88%、93%和91%,均高于血清HE4（81%、81%、82%）与CA125（73%、83%、83%）的单项检测。结论血清HE4与CA125联合检测对卵巢癌的诊断有重要意义,可以提高卵巢癌的诊断效能,对卵巢癌的早鉴别、早诊断、早治疗具有重要价值,值得在临床进行推广应用。

Objective To study and explore diagnostic value of combined detection of tumor marker serum human epididymis secretory protein 4（HE4） and carbohydrate antigen 125（CA125） in ovarian cancer. Methods 100 patients with ovarian cancer who were admitted to our hospital from July 2013 to July 2015 were selected as the observation group and 100 healthy people were selected as the control group. Serum HE4 of 100 patients with ovarian cancer in the observation group and 100 healthy people in the control group were detected by enzyme linked immunoassay（ELISA）. And CA125 level of them were detected by Electrochemiluminescence immunoassay（ECLIA）. Detective statistics were received statistical analysis to explore diagnostic value of single or combined detection of two markers in ovarian cancer. Results Serum HE4 and CA 125 levels of the observation group were significantly improved when compared with those of the control group and the difference had statistical significance（P〈0.05）. Diagnostic results of combined detection of serum HE4 and CA 125 showed that its sensitivity, specificity and accuracy were 88%, 93% and 91% respectively, all higher than those of single detection of HE4（81%, 82%, 73%） and CA125（83%, 81%, 83%）. Conclusion Combined detection of serum HE4 and CA 125 has important significance diagnosis of ovarian cancer which can improve diagnosis efficiency of ovarian cancer. In addition, it has important value for early diagnosis, early diagnosis and early treatment of ovarian cancer, worthy of clinical promotion and application.